Key facts
- It has raised $430K across 1 recorded rounds; the latest was Seed Round ($365K) in Jun 2025.
- Notable investors include Texas Medical Center.
- ReEngage Therapeutics has filed 3 Form Ds with the SEC since 2024, most recently Jul 2025 ($365K sold to 6 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ReEngage Therapeutics
Funding rounds
1 roundsAbout ReEngage Therapeutics
Operator of biopharmaceutical therapies designed to treat longevity-related diseases. The company offers drugs targeting epigenetic modifications associated with aging, enabling advancements in treating neurodegeneration, cancer, and other age-related disorders.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2024
- Employees
- 3
- Website
- reengagetx.com/
- Ownership
- Privately Held (backing)
ReEngage Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ReEngage Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ReEngage Therapeutics in its N-PORT filings yet. We sweep new filings monthly.